Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 46 to 60 of 64 results for metastatic prostate cancer

  1. Ipatasertib with abiraterone and prednisone for hormone-relapsed metastatic prostate cancer [ID3889]

    In development [GID-TA10779] Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Apalutamide for treating non-metastatic, hormone-relapsed prostate cancer [ID1174]

    Discontinued [GID-TA10377]

    Technology appraisal guidance
    Discontinued

  3. The Oncentra Prostate v4.x for ultrasound‑guided real‑time HDR brachytherapy in men with localised prostate cancer (MIB16)

    NICE has developed a Medtech Innovation Briefing (MIB) on the Oncentra Prostate v4.x ultrasound-guided real-time HDR brachytherapy in men with localised

    Medtech innovation briefing
    Published
    16 December 2014

  4. Microwave ablation for primary or metastatic cancer in the lung (IPG716)

    Evidence-based recommendations on microwave ablation for primary or metastatic cancer in the lung in adults. This involves inserting a probe into the lung, through the skin of the chest, to send microwaves into the cancer cells. This produces heat, aiming to destroy the cancer (ablation).

    Interventional procedures guidance
    Published
    2 February 2022
    View recommendations

    Sections for IPG716

  5. Apalutamide with abiraterone acetate and prednisone for treating metastatic hormone-relapsed prostate cancer [ID1480]

    Discontinued [GID-TA10465]

    Technology appraisal guidance
    Discontinued

  6. Prostate cancer (hormone relapsed, metastatic) - rilimogene galvacirepvec (with rilimogene glafolivec, chemotherapy-naive) [ID1018]

    Discontinued [GID-TA11177]

    Technology appraisal guidance
    Discontinued

  7. NICE supports the manufacturer's ongoing commitment to collect data on the effectiveness of enzalutamide after previous treatment with abiraterone.

    applicable) The use of enzalutamide for treating metastatic hormone-relapsed prostate cancer previously...

    Research recommendation
    Published
    9 June 2015

  8. Pembrolizumab with enzalutamide for treating metastatic hormone-relapsed prostate cancer [ID5103]

    In development [GID-TA11004] Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Research recommendations

    increased risk of colorectal cancer:- How effective are colonoscopic surveillance programmes in improving overall survival and...

  10. Hormone-sensitive metastatic prostate cancer: docetaxel (ESUOM50)

    This evidence summary has been updated and replaced by NICE guideline NG131.

    Evidence summary
    Published
    5 January 2016

  11. Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer (TA831)

    This guidance has been updated and replaced by NICE technology appraisal guidance 887.

    Technology appraisal guidance
    Published
    5 October 2022

  12. Abemaciclib with abiraterone acetate and prednisone for treating hormone-relapsed metastatic prostate cancer [ID6230]

    In development [GID-TA11252] Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Cabazitaxel for hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen (TA255)

    This guidance has been updated and replaced by NICE technology appraisal guidance 391.

    Technology appraisal guidance
    Published
    11 May 2012

  14. Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer (CG164)

    This guideline covers care for people with a family history of breast, ovarian or another related (prostate or pancreatic) cancer. It aims to improve the long-term health of these families by describing strategies to reduce the risk of and promote early detection of breast cancer (including genetic testing and mammography). It also includes advice on treatments (tamoxifen, raloxifene) and surgery (mastectomy).

    Clinical guideline
    Last updated
    14 November 2023
    View recommendations

    Sections for CG164

  15. Denosumab for the treatment of therapy-induced bone loss in non-metastatic prostate cancer (terminated appraisal) (TA194)

    This guidance has been updated and replaced by NICE guideline CG175.

    Technology appraisal guidance
    Published
    28 July 2010